Shuimu BioSciences, a pioneering Chinese start-up, is making strides in the development of advanced imaging devices for viruses and smaller biomolecules. The company, which has recently launched its first self-developed product, is targeting an initial public offering by 2027, as stated by CEO Allen Guo Chunlong. Specializing in cryo-electron microscopy (Cryo-EM), Shuimu uses this cutting-edge technique to capture detailed three-dimensional structures of biomolecules like proteins. This technology, once dominated by international companies such as Thermo Fisher Scientific, is now seeing Chinese innovation with Shuimu’s entry into the field. The start-up, founded in 2017 in Beijing, emerged from a collaboration between Tsinghua University, the Beijing municipal government, and Thermo Fisher, aiming to advance Cryo-EM in drug discovery.
Is a Chinese start-up set to revolutionize 3D biomolecular imaging by 2027?
